한국비엔씨

256840KOSDAQ기초 의약물질 제조업

38.0 / 100

Reference Date: 2026-04-13

Financial Score15.5 / 40

News Sentiment12.5 / 25

Momentum3.0 / 20

Disclosure7.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but PER raises overvaluation concerns. Declined 8.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Korea BNC is a biotech company established in 2007, specializing in the research, development, and distribution of medical devices, aesthetic equipment, pharmaceuticals, and cosmeceutical products based on hyaluronic acid and collagen. Its main revenue streams include aesthetic medical products (58.2%) and reagents/test equipment (25.2%), with growth driven by global partnerships in the medical and bio sectors.

Number of Employees

295people

Average Salary

49.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

124.82Industry Average 33.450.0Point

3.7x industry avg (risky)

PBR

1.07Industry Average 2.035.5Point

Lower than industry avg (good)

ROE

0.86Industry Average -4.293.5Point

Well below industry avg

Debt Ratio

9.67Industry Average 6.612.0Point

Higher than industry avg (caution)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.8% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼3.9% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 6.6% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 50

Positive
한국비엔씨 “대구고법, 의약품 회수·폐기·제조중지 명령 취소”
한국비엔씨는 의약품 회수·폐기 및 잠정 제조 중지 명령 취소 소송 2심에서도 승소하여 1심 판결이 정당하다고 인정받았다.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 3,735Won52-week high 6,05052-week low 3,665

1-month return1.0Point

1m -8.23% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

9 totalPositive 0Neutral 8Negative 1

Neutral[기재정정]사업보고서 (2025.12)2026-04-08
Neutral상호변경안내2026-03-31
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
Neutral정기주주총회결과2026-03-31
Neutral기업가치제고계획(자율공시)2026-03-31